Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma
Authors:
- Jose Alejandro Rauh-HainJRJose Alejandro Rauh-Hain
- Matthew Withiam-LeitchMWMatthew Withiam-Leitch
- Bo RuedaBRBo Rueda
- Annekathryn GoodmanAGAnnekathryn Goodman
- Marcela G. del CarmenMCMarcela G. del Carmen
- 1 September 2008
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 110 (3) , 293-298
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Uterine papillary serous carcinoma (UPSC): a single institution review of 129 casesGynecologic Oncology, 2003
- Clear-cell and papillary serous cancer: treatment optionsBest Practice & Research Clinical Obstetrics & Gynaecology, 2001
- Extended Surgical Staging for Uterine Papillary Serous Carcinoma: Survival Outcome of Locoregional (Stage I–III) DiseaseGynecologic Oncology, 2001
- Uterine Papillary Serous Carcinoma: Evaluation of Long-Term Survival in Surgically Staged PatientsGynecologic Oncology, 1998
- Papillary Serous and Clear Cell Type Lead to Poor Prognosis of Endometrial Carcinoma in Black WomenGynecologic Oncology, 1997
- Endometrial Papillary Serous Carcinoma: Patterns of Spread and TreatmentClinical Obstetrics and Gynecology, 1996
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group studyAnnals of Oncology, 1996
- Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervixAmerican Journal of Obstetrics and Gynecology, 1984
- Uterine papillary serous carcinomaAmerican Journal of Surgical Pathology, 1982